-
Clinical Trials & Development2 weeks agoNovartis Remibrutinib, a High-Efficacy Oral BTK Inhibitor, Significantly Reduces Relapse Rates and Shows Favorable Safety Profile in Phase III RMS Trials
Basel, September 1, 2026 – Novartis today announced positive topline results from its Phase III REMODEL-1/-2 trials of remibrutinib in relapsing multiple sclerosis.1 Remibrutinib, a highly...
-
Clinical Trials & Development2 weeks agoESC 2026: The drug development readouts that stood out
Find out what came out of the ESC Congress 2026, from phase 3 successes and failures to earlier-stage programs. The post ESC 2026: The drug development readouts...
Drug Discovery & Therapeutics12 hours ago
Carbon Dots Emerge as a Powerful Weapon Against Superbugs and Biofilms
Clinical Trials & Development12 hours ago
Your Zip Code May Shape Your Breast Cancer Tumor’s Genetics and Your Survival Odds
Drug Discovery & Therapeutics12 hours ago
Azithromycin Resistance in Gonorrhea Shifts Genetic Ground, Challenging Molecular Surveillance
Fierce Biotech6 months ago
Scientists turn pig semen extract into eye drops that kill cancer in mice
Endpoints News6 months ago
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
Uncategorized6 months ago
